Deutsche Bank Initiates Coverage On Sutro Biopharma with Buy Rating, Announces Price Target of $12
Portfolio Pulse from Benzinga Newsdesk
Deutsche Bank analyst James Shin has initiated coverage on Sutro Biopharma (NASDAQ:STRO) with a Buy rating and a price target of $12.
November 09, 2023 | 9:59 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Deutsche Bank has initiated coverage on Sutro Biopharma with a Buy rating and a price target of $12.
The Buy rating and price target set by Deutsche Bank indicate a positive outlook for Sutro Biopharma. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100